A Pre-post Rehabilitation Study of Exosomal mRNA and lncRNA Expression Profiles Reveals Potential Role of UBE2G1 in Rehabilitation of Parkinson’s Disease
Abstract
Objective Long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) are implicated in the development and progression of Parkinson’s disease (PD). This study aims to examine the potential of any lncRNA as biomarkers underlying PD rehabilitation. Methods Pre-post rehabilitation study of lncRNA and mRNA expression profiles may identify the potential biomarkers associated with rehabilitation. We enrolled 6 patients with PD (PWP) and 6 age- and sex-matched healthy controls (HCs) in this study. Peripheral blood samples were collected before and after 14-day rehabilitation treatment to extract total RNA from exosomes. Differentially expressed mRNAs (DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were identified by next-generation sequencing (NGS). A co-expression network was built. Results Overall, pre-post rehabilitation study of exosomal mRNA revealed 1,662 DEmRNAs (606 upregulated and 1,056 downregulated) in PWPs. Compared with the HCs, 1,723 DElncRNAs (1,278 upregulated and 445 downregulated lncRNAs) and 1,931 DElncRNAs (1,561 upregulated and 370 downregulated) were identified in the blood exosomes of pre-rehab and post-rehab PWPs, respectively. GO and KEEG enrichment analyses revealed significant enrichment of proteasome-mediated ubiquitin-dependent protein catabolic process, and ubiquitin mediated proteolysis pathways, suggesting their potential role in the progression of PD. Co-expression network analysis identified one DElncRNA (ENST00000421331) and one positively related DEmRNA (ENSG00000132388, UBE2G1). RT-qPCR validated that ENST00000421331 and ENSG00000132388 were significantly downregulated in the pre-rehab PWPs compared with the HCs ( P < 0.05), but significantly upregulated in the post-rehab PWPs compared with the pre-rehab PWPs ( P < 0.01). Conclusion This is the first report about the role of UBE2G1 in rehabilitation of PD patients. The preliminary findings suggest that UBE2G1 is implicated in PD rehabilitation. Correlation analyses between changes in UBE2G1/lncRNA expression and clinical outcomes, mechanistic study, and longitudinal validation are required to further confirm the role of UBE2G1 as a biomarker in PD rehabilitation.
Related
- WALK for Freezing of Gait in Parkinson's Disease: A Sham-Controlled Home Rehabilitation Trial
- Effectiveness of Virtual Reality-Based Rehabilitation on Balance, Gait, and Functional Independence in Patients With Parkinson’s Disease: Implications for Healthy Longevity
- MUSIC‐PD: A Delphi‐Derived, Culturally Adaptable Music Therapy Protocol for Parkinson's Disease Rehabilitation
- Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches
- Clinical profiles, referral patterns and low vision aid prescribing across four rehabilitation centres in Ghana: protocol for a multicentre retrospective record review
BibTeX
@article{wang2026prepost,
title = {{A Pre-post Rehabilitation Study of Exosomal mRNA and lncRNA Expression Profiles Reveals Potential Role of UBE2G1 in Rehabilitation of Parkinson’s Disease}},
author = {Yixuan Wang and Yonghong Liu and Boyan Fang and Cui Liu and Keke Chen and Detao Meng and Zhaohui Jin},
journal = {Journal of Central Nervous System Disease},
year = {2026},
month = nov,
doi = {10.1177/11795735261506394},
url = {https://doi.org/10.1177/11795735261506394},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Pre-post Rehabilitation Study of Exosomal mRNA and lncRNA Expression Profiles Reveals Potential Role of UBE2G1 in Rehabilitation of Parkinson’s Disease
AU - Yixuan Wang
AU - Yonghong Liu
AU - Boyan Fang
AU - Cui Liu
AU - Keke Chen
AU - Detao Meng
AU - Zhaohui Jin
PY - 2026
DA - 2026/11/04
JO - Journal of Central Nervous System Disease
DO - 10.1177/11795735261506394
UR - https://doi.org/10.1177/11795735261506394
AB - Objective Long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) are implicated in the development and progression of Parkinson’s disease (PD). This study aims to examine the potential of any lncRNA as biomarkers underlying PD rehabilitation. Methods Pre-post rehabilitation study of lncRNA and mRNA expression profiles may identify the potential biomarkers associated with rehabilitation. We enrolled 6 patients with PD (PWP) and 6 age- and sex-matched healthy controls (HCs) in this study. Peripheral blood samples were collected before and after 14-day rehabilitation treatment to extract total RNA from exosomes. Differentially expressed mRNAs (DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were identified by next-generation sequencing (NGS). A co-expression network was built. Results Overall, pre-post rehabilitation study of exosomal mRNA revealed 1,662 DEmRNAs (606 upregulated and 1,056 downregulated) in PWPs. Compared with the HCs, 1,723 DElncRNAs (1,278 upregulated and 445 downregulated lncRNAs) and 1,931 DElncRNAs (1,561 upregulated and 370 downregulated) were identified in the blood exosomes of pre-rehab and post-rehab PWPs, respectively. GO and KEEG enrichment analyses revealed significant enrichment of proteasome-mediated ubiquitin-dependent protein catabolic process, and ubiquitin mediated proteolysis pathways, suggesting their potential role in the progression of PD. Co-expression network analysis identified one DElncRNA (ENST00000421331) and one positively related DEmRNA (ENSG00000132388, UBE2G1). RT-qPCR validated that ENST00000421331 and ENSG00000132388 were significantly downregulated in the pre-rehab PWPs compared with the HCs ( P < 0.05), but significantly upregulated in the post-rehab PWPs compared with the pre-rehab PWPs ( P < 0.01). Conclusion This is the first report about the role of UBE2G1 in rehabilitation of PD patients. The preliminary findings suggest that UBE2G1 is implicated in PD rehabilitation. Correlation analyses between changes in UBE2G1/lncRNA expression and clinical outcomes, mechanistic study, and longitudinal validation are required to further confirm the role of UBE2G1 as a biomarker in PD rehabilitation.
SN - 1179-5735
ER -